NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting
The Californer/10312272

SAN DIEGO, April 29, 2025 ~ San Diego-based biotechnology company NEUVOGEN, Inc. is set to unveil groundbreaking data on their next generation whole tumor cell vaccine, NGEN-143. The company's Chief Executive Officer, Todd Binder, believes that these findings will solidify NGEN-143 as a superior option for cancer patients.

According to Binder, the data shows that NGEN-143 has the ability to activate T cells that recognize a diverse range of antigens. This sets it apart from other cancer vaccines currently available on the market. The company's dedicated team is eager to bring this new vaccine forward and use it to treat patients with non-small cell lung cancer (NSCLC).

The key findings of the study reveal that in a fully human in vitro system, NGEN-143 effectively expands effector T cells against a broad repertoire of both tumor-associated antigens and common shared neo-antigens across a wide range of HLA types. Additionally, the vaccine activates polyfunctional, cytotoxic T cells without any evidence of antigenic competition. The response is dominated by CD8+ cells and CD4+ T cell responses are skewed towards CD4+ Th1 cells over CD4+ Th2 cells.

More on The Californer

• Nieves Ministries Leads with Faith to Fortify Safety, Education, and Puerto Rican Culture in Colorado
• San Francisco Hometown Star Terri J. Vaughn Hits Streaming Highs in Tyler Perry Studios "She the People" on Netflix
• Study: 78% of US Workers Have Chronic Conditions Despite Falling Disability Claims
• Hollywood Burbank Airport Joins Living Advantage, Inc. at V.I.P. Career Match Day!
• California: Governor Newsom announces appointments 5.30.25

Furthermore, NGEN-143 has been shown to efficiently kill human tumor cells in a caspase-3 dependent manner. In mouse tumor models, the vaccine has demonstrated promising results in both "immune warm" and "immune cold" tumors. In the CT26 model, it abrogates or slows tumor growth and provides durable protection against rechallenge. When combined with αPD1 therapy, it has shown improved survival rates compared to monotherapy.

NEUVOGEN's Vice President of Immuno-oncology, Bernadette Ferraro, Ph.D., will be presenting these findings at the American Association for Cancer Research (AACR) conference on Tuesday, April 29 from 2:00 – 5:00 PM CT. The presentation, titled "An optimized off-the-shelf whole tumor cell vaccine activates T cells that recognize a diverse antigen repertoire with potential to provide meaningful clinical benefit to patients with NSCLC," will be available for download on the company's website, neuvogen.com/our-science, after the conclusion of the conference. NEUVOGEN is excited about the potential of NGEN-143 and its ability to revolutionize cancer treatment.

---

Show All News | Report Violation